Dr. Babar Bashir, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 145
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
PA license MD452546 -
Internal Medicine Physician
PA license MT198506 · PA license MD452546
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Thomas Jefferson University Hospital Philadelphia, PA
- Jefferson Stratford Hospital Stratford, NJ
Medical groups
- Jefferson University Physicians (1,531 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 145
- Services billed
- 458
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 187 | 53 |
| Established patient office or other outpatient visit, 40-54 minutes | 57 | 24 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Philadelphia, PA | 41 |
| Prochlorperazine Maleate Other prescribers in Philadelphia, PA | 40 |
| Loperamide (loperamide hcl) Other prescribers in Philadelphia, PA | 19 |
| Creon (lipase/protease/amylase) Other prescribers in Philadelphia, PA | 16 |
| Olanzapine Other prescribers in Philadelphia, PA | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 5 payments worth $473 in total to this clinician.
| Tempus Ai, Inc | $168 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $130 |
| Genzyme Corporation | $105 |
| Janssen Research & Development, LLC | $37.53 |
| Janssen Scientific Affairs, LLC | $32.79 |
| Food and Beverage | $473 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $1,412,922 in research payments for these studies, mostly to the institutions running them.
- Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen Inc. - A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.…
Amgen Inc. - Phase 1b of SOF10 in patients with solid tumors
Genentech, Inc. - The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Incyte Corporation - A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation - A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Ch…
Janssen Research & Development, LLC - A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
Janssen Research & Development, LLC - An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of N0112 in Human Leukocyte Antigen-C0802-Positive Adult Subjects with Unresectable, Advanced, and/or Metastatic Sol…
AstraZeneca Pharmaceuticals LP - Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer …
Amgen Inc. - A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie Inc. · Active, not recruiting · NCT06614192
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.